{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:38:36Z","timestamp":1790231916919,"version":"4.1.0"},"reference-count":64,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2000,3,13]]},"abstract":"<jats:p> PURPOSE: To determine clinical practice guidelines for the use of bisphosphonates in the prevention and treatment of bone metastases in breast cancer and their role relative to other therapies for this condition. <\/jats:p><jats:p> METHODS: An expert multidisciplinary panel reviewed pertinent information from the published literature and meeting abstracts through May 1999. Additional data collected as part of randomized trials and submitted to the United States Food and Drug Administration were also reviewed, and investigators were contacted for more recent information. Values for levels of evidence and grade of recommendation were assigned by expert reviewers and approved by the panel. Expert consensus was used if there were insufficient published data. The panel addressed which patients to treat and when in their course of disease, specific drug delivery issues, duration of therapy, management of bony metastases with other therapies, and the public policy implications. The guideline underwent external review by selected physicians, members of the American Society of Clinical Oncology (ASCO) Health Services Research Committee, and the ASCO Board of Directors. <\/jats:p><jats:p> RESULTS: Bisphosphonates have not had an impact on the most reliable cancer end point: overall survival. The benefits have been reductions in skeletal complications, ie, pathologic fractures, surgery for fracture or impending fracture, radiation, spinal cord compression, and hypercalcemia. Intravenous (IV) pamidronate 90 mg delivered over 1 to 2 hours every 3 to 4 weeks is recommended in patients with metastatic breast cancer who have imaging evidence of lytic destruction of bone and who are concurrently receiving systemic therapy with hormonal therapy or chemotherapy. For women with only an abnormal bone scan but without bony destruction by imaging studies or localized pain, there is insufficient evidence to suggest starting bisphosphonates. Starting bisphosphonates in patients without evidence of bony metastasis, even in the presence of other extraskeletal metastases, is not recommended. Studies of bisphosphonates in the adjuvant setting have yielded inconsistent results. Starting bisphosphonates in patients at any stage of their nonosseous disease, outside of clinical trials, despite a high risk for future bone metastasis, is currently not recommended. Oral bisphosphonates are one of several options which can be used for preservation of bone density in premenopausal patients with treatment-induced menopause. The panel suggests that, once initiated, IV bisphosphonates be continued until evidence of substantial decline in a patient\u2019s general performance status. The panel stresses that clinical judgment must guide what is a substantial decline. There is no evidence addressing the consequences of stopping bisphosphonates after one or more adverse skeletal events. Symptoms in the spine, pelvis, or femur require careful evaluation for spinal cord compression and pathologic fracture before bisphosphonate use and if symptoms recur, persist, or worsen during therapy. The panel recommends that current standards of care for cancer pain, analgesics and local radiation therapy, not be displaced by bisphosphonates. IV pamidronate is recommended in women with pain caused by osteolytic metastasis to relieve pain when used concurrently with systemic chemotherapy and\/or hormonal therapy, since it was associated with a modest pain control benefit in controlled trials. <\/jats:p><jats:p> CONCLUSION: Bisphosphonates provide a meaningful supportive but not life-prolonging benefit to many patients with bone metastases from cancer. Further research is warranted to identify clinical predictors of when to start and stop therapy, to integrate their use with other treatments for bone metastases, to identify their role in the adjuvant setting in preventing bone metastases, and to better determine their cost-benefit consequences. <\/jats:p>","DOI":"10.1200\/jco.2000.18.6.1378","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T02:16:39Z","timestamp":1487902599000},"page":"1378-1391","source":"Crossref","is-referenced-by-count":288,"title":["American Society of Clinical Oncology Guideline on the Role of Bisphosphonates in Breast Cancer"],"prefix":"10.1200","volume":"18","author":[{"given":"Bruce E.","family":"Hillner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James N.","family":"Ingle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Berenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora A.","family":"Janjan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy S.","family":"Albain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Lipton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Sybil","family":"Biermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowan T.","family":"Chlebowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the American Society of Clinical Oncology Bisphosphonates Expert Panel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1-0204","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.48.1.6"},{"key":"R2-0204","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-196809000-00004"},{"key":"R4-0204","unstructured":"Canadian Medical Association: The Canadian task force on the periodic health examination.  Can Med Assoc J 121:1193,1979-1254,"},{"key":"R5-0204","doi-asserted-by":"crossref","unstructured":"Cook  DL,  Guyatt  GH,  Laupacis  A, et al:  Rules of evidence and clinical recommendations on the use of antithrombotic agents.  Chest 102:305S,1992-311S,   (suppl 4)","DOI":"10.1378\/chest.102.4_Supplement.305S"},{"key":"R6-0204","doi-asserted-by":"publisher","DOI":"10.1378\/chest.95.1.2"},{"key":"R7-0204","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.9.3204"},{"key":"R8-0204","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1668::AID-CNCR17>3.0.CO;2-Y"},{"key":"R9-0204","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(97)10136-8"},{"key":"R10-0204","doi-asserted-by":"publisher","DOI":"10.1210\/edrv.19.1.0325"},{"key":"R11-0204","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199612123352401"},{"key":"R12-0204","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.6.2038"},{"key":"R13-0204","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.3.846"},{"key":"R14-0204","doi-asserted-by":"publisher","DOI":"10.1007\/BF00355241"},{"key":"R15-0204","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.9.2552"},{"key":"R16-0204","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.1.59"},{"key":"R17-0204","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.3.491"},{"key":"R18-0204","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.3.1218"},{"key":"R19-0204","doi-asserted-by":"crossref","unstructured":"British Association of Surgical Oncology guidelines: The management of metastatic bone disease in the United Kingdom\u2014The Breast Specialty Group of the British Association of Surgical Oncology.  Eur J Surg Cancer 25:3,1999-23,","DOI":"10.1053\/ejso.1998.0593"},{"key":"R20-0204","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.12.3890"},{"key":"R21-0204","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19861215)58:12<2589::AID-CNCR2820581206>3.0.CO;2-O"},{"key":"R22-0204","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1996.298"},{"key":"R23-0204","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-7372(96)90021-3"},{"key":"R24-0204","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(98)00277-9"},{"key":"R25-0204","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19941201)74:11<2949::AID-CNCR2820741110>3.0.CO;2-Q"},{"key":"R26-0204","doi-asserted-by":"publisher","DOI":"10.1007\/s005200050218"},{"key":"R27-0204","doi-asserted-by":"publisher","DOI":"10.1016\/0885-3924(92)90101-M"},{"key":"R28-0204","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(97)00075-4"},{"key":"R29-0204","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1686::AID-CNCR20>3.0.CO;2-V"},{"key":"R30-0204","doi-asserted-by":"publisher","DOI":"10.1016\/S8756-3282(96)00285-2"},{"key":"R31-0204","doi-asserted-by":"crossref","unstructured":"van Holten-Verzantvoort  AT,  Hermans  J,  Beex  LV, et al:  Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patients?  Eur J Cancer 32A:450,1996-454,","DOI":"10.1016\/0959-8049(95)00564-1"},{"key":"R32-0204","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.50.1.237"},{"key":"R33-0204","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808063390601"},{"key":"R34-0204","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.9.704"},{"key":"R35-0204","unstructured":"Saarto  T,  Blomqvist  C,  Virkkunen  P, et al:  No reduction of bony metastases with adjuvant clodronate treatment in node-positive breast cancer patients.  Proc Am Soc Clin Oncol 19:128a,1999  (abstr 489)"},{"key":"R36-0204","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6690188"},{"key":"R37-0204","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.3.955"},{"key":"R38-0204","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1997.105"},{"key":"R39-0204","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.4.1341"},{"key":"R40-0204","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)11423-4"},{"key":"R41-0204","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1988.136"},{"key":"R42-0204","doi-asserted-by":"crossref","unstructured":"Love  RR,  Mazess  RB,  Tormey  DC, et al:  Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years.  Breast Cancer Res Treat 12:297,1998-302,","DOI":"10.1007\/BF01811242"},{"key":"R43-0204","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.6.1939"},{"key":"R44-0204","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.18.1371"},{"key":"R45-0204","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803123381107"},{"key":"R46-0204","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.6.1680"},{"key":"R47-0204","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.1.130"},{"key":"R48-0204","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-199812020-00007"},{"key":"R49-0204","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.2.593"},{"key":"R50-0204","doi-asserted-by":"crossref","unstructured":"Tyrrell  CT,  Bruning  PF,  May-Levin  F, et al:  Pamidronate infusions as single-agent therapy for bone metastases:  A phase II trial in patients with breast cancer. Eur J Cancer 31A:1976,1995-1980,","DOI":"10.1016\/0959-8049(95)00469-6"},{"key":"R51-0204","unstructured":"Vilimovskij  A,  Thuerlimann  JR,  Berenson  JR, et al:  Renal safety and tolerability of 90 mg of Aredia (pamidronate) administered as an intravenous 1 hour infusion:  Preliminary results. Proc Am Soc Clin Oncol 19:576a,1999  (abstr 2223)"},{"key":"R52-0204","doi-asserted-by":"crossref","unstructured":"Yazawa  Y,  Frassica  FJ,  Chao  EY, et al:  Metastatic bone disease:  A study of the surgical treatment of 166 pathologic humeral and femoral fractures. Clin Orthop 251:213,1990-219,","DOI":"10.1097\/00003086-199002000-00036"},{"key":"R53-0204","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(97)00952-8"},{"key":"R55-0204","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(92)90565-Y"},{"key":"R56-0204","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1995.03530050068035"},{"key":"R58-0204","unstructured":"Petru  E,  Schmahl  D:  On the relevance of \u201csecond-line\u201d cytotoxic chemotherapy in patients with metastatic breast cancer resistant to standard combinations.  Wien Klin Wochenschr 98:790,1986-797,"},{"key":"R59-0204","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19920701)70:1<129::AID-CNCR2820700122>3.0.CO;2-Y"},{"key":"R60-0204","doi-asserted-by":"publisher","DOI":"10.1007\/BF01975000"},{"key":"R61-0204","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006285726561"},{"key":"R62-0204","doi-asserted-by":"publisher","DOI":"10.1007\/BF01806525"},{"key":"R63-0204","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.1.55"},{"key":"R64-0204","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.1.72"},{"key":"R65-0204","unstructured":"Balducci  L:  Cost effectiveness of pamidronate in the treatment of breast cancer in the metastatic and in the adjuvant setting.  Proc Am Soc Clin Oncol 17:415a,1999  (abstr 1599)"},{"key":"R66-0204","doi-asserted-by":"publisher","DOI":"10.1007\/s005200050260"},{"key":"R68-0204","unstructured":"Body  JJ,  Lichinitser  I,  Diehl  K, et al:  Double-blind placebo-controlled trial of intravenous ibandronate in breast cancer metastatic to bone.  Proc Am Soc Clin Oncol 19:575a,1999  (abstr 2222)"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2000.18.6.1378","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T17:43:54Z","timestamp":1653500634000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2000.18.6.1378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,3,13]]},"references-count":64,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2000,3,13]]}},"alternative-id":["10.1200\/JCO.2000.18.6.1378"],"URL":"https:\/\/doi.org\/10.1200\/jco.2000.18.6.1378","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,3,13]]}}}